Description

Merck’s $1.3 Billion Acquisition: Four Synergies Investors Should Watch!

Germany’s Merck KGaA has announced a definitive agreement to acquire UK-based Silence Therapeutics (NASDAQ) for approximately $1.3 billion in equity value, marking another step in its expansion into specialized medicines. Announced on October 19, 2026, the all-cash transaction offers Silence shareholders $20 per American depositary share, representing a 130% premium to its October 16 closing price. The deal carries an enterprise value of approximately $1.1 billion and would add divesiran, an investigational treatment for the rare blood cancer polycythemia vera, to Merck’s pipeline. Following its acquisition of SpringWorks Therapeutics in 2025, Merck is continuing to pursue external innovation in diseases with substantial unmet medical needs. Silence also brings proprietary short interfering RNA (siRNA) technology capable of selectively suppressing disease-related genes. While the proposed acquisition remains subject to regulatory, shareholder and court approvals, it presents several potential opportunities for Merck to strengthen its pharmaceutical portfolio and development capabilities.